CLINICAL TRIALS PROFILE FOR FRUQUINTINIB
✉ Email this page to a colleague
All Clinical Trials for fruquintinib
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01645215 ↗ | Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors | Completed | Fudan University | Phase 1 | 2011-01-01 | Fruquintinib (HMPL-013) is a novel oral small molecule that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 and has demonstrated potent inhibitory effects on multiple human tumor xenografts. This first-in-human study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate the pharmacokinetics , safety and preliminary anti-tumor activity of HMPL-013 at single doses and multiple doses . |
| NCT01645215 ↗ | Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors | Completed | Hutchison Medipharma Limited | Phase 1 | 2011-01-01 | Fruquintinib (HMPL-013) is a novel oral small molecule that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 and has demonstrated potent inhibitory effects on multiple human tumor xenografts. This first-in-human study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate the pharmacokinetics , safety and preliminary anti-tumor activity of HMPL-013 at single doses and multiple doses . |
| NCT01955304 ↗ | Food Effect Study of Single Dose of Fruquintinib (HMPL-013) in Healthy Subjects | Completed | Hutchison Medipharma Limited | Phase 1 | 2012-06-01 | This study will determine the effect of food on the pharmacokinetics (PK) of a single dose of 4mg fruquintinib in normal healthy subjects. |
| NCT01975077 ↗ | A Phase Ib Study of Fruquintinib in 3rd Line mCRC | Completed | Fudan University | Phase 1/Phase 2 | 2012-12-01 | Fruquintinib is a novel oral small molecule compound discovered and developed by Hutchison MediPharma that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 and has demonstrated potent inhibitory effects on multiple human tumor xenografts.Based on first-in-human study, both 4mg QD and 5mg 3wks on/1wk off are safety and efficacy, this phase Ib study is to evaluable the safety, tolerability and efficacy of these 2 regimens with mCRC failed 2nd therapy or more and to determine the recommended dose and regimen in phase II/III study. |
| NCT01975077 ↗ | A Phase Ib Study of Fruquintinib in 3rd Line mCRC | Completed | Sun Yat-sen University | Phase 1/Phase 2 | 2012-12-01 | Fruquintinib is a novel oral small molecule compound discovered and developed by Hutchison MediPharma that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 and has demonstrated potent inhibitory effects on multiple human tumor xenografts.Based on first-in-human study, both 4mg QD and 5mg 3wks on/1wk off are safety and efficacy, this phase Ib study is to evaluable the safety, tolerability and efficacy of these 2 regimens with mCRC failed 2nd therapy or more and to determine the recommended dose and regimen in phase II/III study. |
| NCT01975077 ↗ | A Phase Ib Study of Fruquintinib in 3rd Line mCRC | Completed | Hutchison Medipharma Limited | Phase 1/Phase 2 | 2012-12-01 | Fruquintinib is a novel oral small molecule compound discovered and developed by Hutchison MediPharma that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 and has demonstrated potent inhibitory effects on multiple human tumor xenografts.Based on first-in-human study, both 4mg QD and 5mg 3wks on/1wk off are safety and efficacy, this phase Ib study is to evaluable the safety, tolerability and efficacy of these 2 regimens with mCRC failed 2nd therapy or more and to determine the recommended dose and regimen in phase II/III study. |
| NCT02196688 ↗ | Study of Fruquintinib in Patients With Metastatic Colorectal Cancer | Completed | Fudan University | Phase 2 | 2014-04-01 | Fruquintinib administered at 5mg once daily in 4 weeks treatment cycle (three weeks on and one week off) was well tolerated and demonstrated encouraging preliminary clinical antitumor activity in patients with advanced Colorectal Cancer (CRC) in Phase Ib study. This study is aimed to evaluate the efficacy and safety of Fruquintinib in the treatment of patients with metastatic CRC who have progressed after metastatic CRC second line or above standard chemotherapy. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for fruquintinib
Condition Name
Clinical Trial Locations for fruquintinib
Trials by Country
Clinical Trial Progress for fruquintinib
Clinical Trial Phase
Clinical Trial Sponsors for fruquintinib
Sponsor Name
